Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2012; 18(43): 6226-6234
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6226
Figure 3
Figure 3 Effects of U0126, protein kinase B inhibitor XIV and erlotinib on proliferation of BxPC-3 and Capan-1 cells. The cells were seeded in 96 half-area well plates, starved from serum and treated with protein kinase B (AKT) inhibitor XIV or mitogen-activated protein kinase kinase inhibitor U0126 in the presence or absence of erlotinib for a total of 32 h. DNA synthesis was measured by 5-bromo-2'-deoxyuridine (BrdU) incorporation over the last 8 h. Data represent mean ± SE (n = 6), aP < 0.05 vs cultures with erlotinib only. P < 0.05 between all samples vs untreated cells (not indicated in the figure).